The biotech had hinted the agency might finally issue a decision on whether to grant new molecular entity status to its Vascepa fish oil pill, which was approved last July to treat people with seriously high levels of triglycerides.

FORBES: For Amarin And Its Fish Oil Pill, Another FDA Delay